Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys

European Journal of Pharmacology

Volumn 412, Issue 3, 2001, Pages 247-254

  Tahar, Abdallah Hadj ^a   Ekesbo, Anna ^b   Grégoire, Laurent ^a   Bangassoro, Evelyne ^a   Svensson, Kjell A ^c   Tedroff, Joakim ^b   Bédard, Paul J ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c CNS Diseases Research   (United States)

Author keywords

( ) OSU6162; Dopamine D2 receptor; Dyskinesias; L DOPA; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; BENSERAZIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENERVATION; DRUG EFFECT; DYSKINESIA; INVOLUNTARY MOVEMENT; LIGAND BINDING; LIGHT DARK CYCLE; LONG TERM EXPOSURE; MONKEY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MACACA FASCICULARIS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PIPERIDINES; RECEPTORS, DOPAMINE D2;

EID: 0035793308     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00737-3     Document Type: Article

References (26)

1. 2 agonists in inducing dyskinesias in drug-naive MPTP monkeys
2. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
3. Pathophysiology of levodopa-induced dyskinesia: Changing concepts
4. 2 agonist (U-91356A) in MPTP-exposed monkeys
5. 2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys
6. Is striatal dopaminergic receptor imbalance responsible for levo-dopa-induced dyskinesias?
7. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesias in Parkinson's disease: Implications for future strategies in treatment
8. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease
9. 11C]raclopride binding in primate brain
10. Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions
11. 2-like receptor agonist, produces a sustained anti-parkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates
12. 1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys
13. 1 receptors improves L-DOPA-induced dyskinesias but worsens parkinsonism in MPTP monkeys
14. Attempted use of haloperidol in the treatment of L-DOPA induced dyskinesias
15. Problems with long-term levodopa therapy for Parkinson's disease
16. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to L-DOPA therapy for Parkinson's disease
17. 11C-methyl]-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography
18. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions
19. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: Synthesis and structure-activity relationships
20. (-)-OSU6162 a representative from a unique class of functional modulators of dopaminergic systems
21. 11C]raclopride displacement and PET
22. 2 receptor?
23. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity
24. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease
25. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications